Marshall H J, Beevers D G
University Department of Medicine, City Hospital, Birmingham, UK.
Br J Clin Pharmacol. 1996 Oct;42(4):507-9. doi: 10.1046/j.1365-2125.1996.45217.x.
There have been occasional reports of female stress incontinence related to prazosin therapy for hypertension. This drug is now rarely used but recently longer acting alpha-adrenoceptor blocking drugs have been introduced. We have, therefore, investigated the prevalence of urinary incontinence in all our female patients who were receiving alpha-adrenoceptor blockers in comparison with women, matched for age and parity who were receiving other drugs. We identified a total of 49 women taking alpha-adrenoceptor blocking drugs (prazosin 4, terazosin 5, doxazosin 40) among current patients who were attending our hypertension clinic. Twenty of these (40.8%) reported some urinary incontinence whereas in the control patients, only 8 (16.3%) had this symptom (P = < 0.02, relative risk 2.5, 95% CI 1.22-5.13). alpha-Adrenoceptor blockers were withdrawn in 18 of the 20 patients with incontinence and in 13, their symptoms abated. Our results suggest that there is a significantly higher prevalence of urinary incontinence in women taking alpha-adrenoceptor antagonists with reversibility on withdrawal of these drugs. As both female urinary incontinence, hypertension and the use of alpha-adrenoceptor blocking drugs are common, this distressing side effect should be borne in mind so that gynaecological or urological treatment may be avoided in some women.
偶尔有报告称，女性压力性尿失禁与使用哌唑嗪治疗高血压有关。这种药物现在很少使用，但最近引入了长效α-肾上腺素能受体阻滞剂。因此，我们调查了所有正在接受α-肾上腺素能受体阻滞剂治疗的女性患者的尿失禁患病率，并与年龄和产次相匹配、正在接受其他药物治疗的女性进行了比较。我们在前来我们高血压诊所就诊的现患患者中，共识别出49名服用α-肾上腺素能受体阻滞剂的女性（哌唑嗪4名、特拉唑嗪5名、多沙唑嗪40名）。其中20名（40.8%）报告有某种程度的尿失禁，而在对照患者中，只有8名（16.3%）有此症状（P = < 0.02，相对风险2.5，95%可信区间1.22 - 5.13）。20名尿失禁患者中有18名停用了α-肾上腺素能受体阻滞剂，其中13名患者的症状减轻。我们的结果表明，服用α-肾上腺素能拮抗剂的女性尿失禁患病率显著更高，停用这些药物后症状可逆转。由于女性尿失禁、高血压以及α-肾上腺素能受体阻滞剂的使用都很常见，应牢记这种令人苦恼的副作用，以便在某些女性中避免进行妇科或泌尿科治疗。
